SURF - Surface Oncology: Neither Novartis Nor GSK Or ARKG Is Able To Stop The Decline May, 25 2022 08:50 AM Surface Oncology Inc. Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. Despite having partnerships with big names, the stock does not move up. For further details see: Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline